What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Modified HGH fragment 176–191 (anti-obesity drug candidate)
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating AOD9604 through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
AOD9604 is a modified analogue of the C-terminal 176-191 fragment of human growth hormone, originally developed at Monash University in Australia as a lipolytic anti-obesity clinical-development candidate. Structurally it is the 16-residue Tyr-hGH(177-191) analogue, sequence YLRIVQCRSVEGSCGF, carrying an N-terminal tyrosine (in place of the phenylalanine that opens the native 176-191 fragment) that was introduced during the preclinical era specifically to support iodination for tracking studies. Pharmacologically, the molecule preserves the C-terminal-region lipolytic activity that drives the published research interest, hypothesised to act through a non-GH-receptor pathway, while leaving behind the broader anabolic effects that the central GH-receptor-binding region of the full-length protein mediates. The asset advanced through Phase 2b clinical trials for obesity but did not reach regulatory approval as a finished drug; in some jurisdictions it has subsequently transitioned to research and dietary-supplement markets. Vialdyne releases AOD9604 as a lyophilised powder against a ≥99.0% main-peak HPLC specification with a batch COA covering RP-HPLC, ESI-MS, water content, and counter-ion. Because the N-terminal tyrosine is the only structural feature separating AOD9604 from the unmodified HGH Fragment 176-191, and because the two molecules are easy to confuse on a catalogue page, buyers should be explicit about which variant they want at the order-placement stage so the lot is reserved correctly. Three standard fills (2, 5, 10 mg) map onto bench-scale aliquots and small-batch dispensing workflows.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Certificate of Analysis
Published released-batch COAs for AOD9604, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →AOD9604
VD260428-AOD10020 · 99.20%
VerifiedRequest full COA →AOD9604
VD260428-AOD018 · 98.95%
VerifiedRequest full COA →AOD9604
VD260428-AOD5019 · 99.10%
Regulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
Treat it as an unapproved bulk active and resolve compounding eligibility before any purchase order. Because the obesity-drug program was discontinued and never reached finished-drug approval, there is no reference-listed product and no compendial monograph to anchor a specification, so the pharmacy writes its own identity-and-purity acceptance criteria and confirms them against each batch certificate. State-board posture toward this molecule varies, so verify your own jurisdiction's stance independently rather than inferring eligibility from another compound in the GH-fragment space. Documentation on file should note the research-use versus dietary-supplement history to support that determination.
This C-terminal fragment ships lyophilised and should stay sealed at -20 C until use, with a documented re-test date carried on the released-batch certificate. Reconstitute in bacteriostatic water for injection at a working concentration, then split into the smallest single-use aliquots immediately, since repeated freeze-thaw cycling drives more measured-potency loss than gradual temperature drift. Hold cumulative thaws to three or fewer per aliquot. Because the molecule lacks the central-region determinants of full-length HGH, do not carry over storage or handling assumptions from recombinant growth-hormone material; qualify and document it on its own terms.
Related peptides
16-mer
C-terminal fragment of human growth hormone (176–191)
29-mer
GHRH 1-29 fragment
Ghrelin / GHSR pathway GH-release peptide
